Treating Elevated Cholesterol Levels: The Great Satan in Perspective
- 8 March 1996
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 36 (3) , 189-197
- https://doi.org/10.1002/j.1552-4604.1996.tb04187.x
Abstract
The purpose of this review is to provide perspective on the developments leading to the recognition of high cholesterol levels as a risk factor for coronary heart disease (CHD). Another objective is to consider the unfolding controversies regarding the relative value of cholesterol‐lowering drug therapy in primary and secondary prevention. Should physicians use lipid‐lowering drugs to treat patients with elevated cholesterol levels but no clinical evidence of coronary disease, or limit intervention to patients with a previous history of angina, coronary angioplasty, coronary artery bypass surgery, or myocardial infarction? This review finds inadequate data to support a recommendation for screening large populations for the presence of elevated cholesterol levels or for primary prevention in those known to have high cholesterol. On the other hand, there is mounting evidence to support vigorous intervention in those with known coronary disease. Further study is needed to determine whether a subset of patients with one or more well‐defined risk factors would benefit from primary prevention.Keywords
This publication has 41 references indexed in Scilit:
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐upJournal of Internal Medicine, 1994
- Cholesterol lowering and mortality: the importance of considering initial level of risk.BMJ, 1993
- Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome.BMJ, 1992
- Position Statement: Cholesterol Screening in Children is Not Indicated, Even With Positive Family HistoryJournal of the American College of Nutrition, 1992
- Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.BMJ, 1990
- Treating HypercholesterolemiaNew England Journal of Medicine, 1989
- Gemfibrozil, Lipids, and Coronary RiskNew England Journal of Medicine, 1987
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Regulation of Plasma Cholesterol by Lipoprotein ReceptorsScience, 1981